{
    "nct_id": "NCT03671018",
    "official_title": "An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma",
    "inclusion_criteria": "* ECOG PS of 0, 1, or 2\n* Histologically confirmed FL, DLBCL, or MCL\n* Must have received at least one prior systemic treatment regimen containing an anti-CD20-directed therapy for DLBCL or FL\n* For MCL, participants must have received at least two prior systemic treatment regiments, which include 1) anti-CD20-directed therapy, 2) BTK inhibitor, and 3) anthracycline or bendamustine\n* Relapsed to prior regimen(s) after having a documented history of response (complete response [CR], CR unconfirmed [CRu], or partial response [PR]) of >/= 6 months in duration from completion of regimen(s); or, refractory to any prior regimen, defined as no response to the prior therapy, or progression within 6 months of completion of the last dose of therapy\n* Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension\n* Adequate hematologic, renal, and hepatic function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies\n* Prior treatment with polatuzumab vedotin\n* Current > Grade 1 peripheral neuropathy\n* Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate (ADC) within 4 weeks before first dose of study treatment\n* Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment\n* Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment\n* Autologous stem-cell transplantation (SCT) within 100 days prior to first study treatment administration\n* Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days before first study treatment administration\n* Prior allogeneic SCT\n* Prior solid organ transplantation\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n* Patients with history of confirmed progressive multifocal leukoencephalopathy (PML)\n* Current or past history of central nervous system (CNS) lymphoma or CNS disease\n* History of autoimmune disease",
    "miscellaneous_criteria": "Key"
}